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Interleukin 1-betaNeuroinﬂammation is a characteristic feature of the Alzheimer’s disease (AD) brain. Signiﬁcant inﬂammatory
markers such as activatedmicroglia and cytokines can be found surrounding the extracellular senile plaques pre-
dominantly composed of amyloid-β protein (Aβ). Several innate immune pathways, including Toll-like receptors
(TLRs) and the NLRP3 inﬂammasome, have been implicated in AD inﬂammation. Aβ plays a primary role in ac-
tivating these pathways which likely contributes to the progressive neurodegeneration in AD. In order to better
understand the complexities of this interaction we investigated the inﬂammatory response of primarymicroglia
to Aβ(1-42) protoﬁbrils. Aβ(1-42) protoﬁbrils triggered a time- and MyD88-dependent process that produced
tumor necrosis factor alpha (TNFα) and interleukin-1β (IL-1β) mRNA, and intracellular pro and mature forms
of IL-1β protein. The accumulation of both IL-1β forms indicated that Aβ(1-42) protoﬁbrils were able to prime
and activate the NLRP3 inﬂammasome. Surprisingly, Aβ-induced accumulation of intracellular mature IL-1β
did not translate into greater IL-1β secretion. Instead, we found that Aβ elicited a quantized burst of secreted
IL-1β and this process occurred even prior to Aβ priming of the microglia suggesting a basal level of either pro
or mature IL-1β in the cultured primary microglia. The IL-1β secretion burst was rapid but not sustained, yet
could be re-evoked with additional Aβ stimulation. The ﬁndings from this study demonstrated multiple sites
of IL-1β regulation by Aβ(1-42) protoﬁbrils including TLR/MyD88-mediated priming, NLRP3 inﬂammasome ac-
tivation, and modulation of the IL-1β secretory process. These results underscore the wide-ranging effects of Aβ
on the innate immune response.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is the most prevalent form of late-life
dementia and has been deﬁned by the presence of two pathological
hallmarks, neuroﬁbrillary tangles (NFTs) and senile (amyloid) plaques.
The NFTs are intracellular lesions of insoluble, highly stable ﬁlamentous
aggregates of the microtubule-associated protein, tau, whereas the se-
nile plaques are extracellular lesions of insoluble, amyloid ﬁbrils that
are polymers of the amyloid-β protein (Aβ) [1,2]. However, Aβ is the
protein that has been found to be most clearly associated to the cause
of AD,while tau protein has shown to bemost closely related to the clin-
ical manifestations of AD [2]. The complexity of AD pathology reaches-β protein; aCSF, artiﬁcial cere-
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.beyond NFTs and amyloid plaques. Recent ﬁndings have shown that
the toxicity of Aβ may be due to soluble oligomeric intermediates
found in the AD brain and cerebrospinal ﬂuid rather than insoluble ﬁ-
brils [3,4]. These soluble oligomeric Aβ forms appear to contribute to
AD onset by causing neuronal and/or synaptic dysfunction [3,5].
There has been an array of different aggregate morphologies of Aβ
found within the AD brain [6]. The core of the Aβ plaques is primarily
composed of the 42-amino acid Aβ fragment, Aβ(1-42). However
Aβ(1-40) has also been found colocalized with the Aβ(1-42) [7]. In
vitro, Aβ monomer undergoes self-assembly by non-covalent interac-
tions to form polydisperse mixtures of soluble oligomers [4] and
protoﬁbrils [8,9]. These soluble aggregates go through a conformational
transition from predominately random coil to increasing amounts of β-
sheet structure and ultimately produce insoluble ﬁbrils [10,11]. As a
precursor to mature ﬁbrils, protoﬁbrils have been fairly well character-
ized and have been shown to alter the normal physiology of cultured
neurons [12], disrupt ion channels [13], block long-term potentiation
(LTP), inhibit synapse remodeling and impair memory consolidation
[14].
A prominent component of AD pathology is neuroinﬂammation
found in the affected areas of the AD brain. Inﬂammatory markers,
such as activated microglia and proinﬂammatory cytokines, are most
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though the exact sequence of events leading to AD is still unclear, it is
thought that Aβ accumulation initiates a pathological cascade of events
leading to neuronal dysfunction and ultimately dementia. One part of
this pathological cascade is an immune cell-mediated inﬂammatory re-
sponse, involving proliferation and activation of microglia and astro-
cytes. The increase in inﬂammation-associated proteins and oxidative
stress by-products is more than just a biomarker of AD [17]. Persistent
inﬂammation can lead to a chronic inﬂammatory state, suggested to
be an underlying mechanism of the progressive neurodegeneration in
AD [16,17].
The innate immune system protects an organism by detection of
invading pathogens via pattern recognition receptors (PRRs). Both
microglia and astrocytes express Toll-like receptors (TLRs), which are
a family of PRRs that recognize pathogen-associated molecular patterns
(PAMPs) within speciﬁc molecules produced by bacteria, fungi, and
viruses [18]. TLR engagement, with the exception of TLR3, leads to the
recruitment of the adaptor protein myeloid differentiation protein 88
(MyD88), activation of the transcription factor nuclear factor-κB (NF-
κB), and expression of a variety of genes involved in the immune re-
sponse, such as tumor necrosis factor-α (TNFα) and interleukin-1β
(IL-1β) [18]. Multiple TLRs and accessory proteins play a role in the pro-
inﬂammatory response evoked by Aβ in monocyte/macrophages and
microglia including CD14, TLR4, and TLR2 [19–23] and TLR4 and TLR6
in concert with CD36 [24]. In addition to TLRs, a multireceptor complex
comprised of scavenger receptor class B (SR-B), CD36, α6β1-integrin
and the integrin-associated protein CD47 has also been shown to inter-
act with Aβ and initiate a proinﬂammatory response [25].
Extracellular recognition of PAMPs by TLRs and downstream sig-
naling events can trigger oligomerization of cytoplasmic Nod-like re-
ceptors (NLRs) to form a multisubunit inﬂammasome complex [26].
Different NLR family members vary in their N-terminal protein–pro-
tein interaction region. For example, NLRP3 contains a pyrin domain
which is responsible for complexation with ASC, the adaptor mole-
cule termed apoptosis-associated speck-like protein containing a
caspase-recruitment domain (CARD) [27]. An important aspect of
TLR signaling is production of IL-1β mRNA and the pro-form of IL-
1β protein (pro-IL-1β). This event is considered “priming” of the
inﬂammasome and represents Signal 1 of a 2-stage process [28].
Many molecules, including the classical TLR4 agonist lipopolysac-
charide (LPS), stimulate priming of the inﬂammasome (Signal 1)
but not activation. Inﬂammasome assembly via a CARD-CARD inter-
action brings caspase-1 to the complex and activation of the complex
triggers caspase-1-catalyzed proteolytic cleavage of pro-IL-1β to
mature IL-1β [29]. A second signal is required for the inﬂammasome
activation step and subsequent production of mature IL-1β. Signal 2
may be provided by a growing number of endogenous human mole-
cules, referred to as danger-associated molecular patterns (DAMPs).
These molecules include certain pore-forming toxins, ATP, K+ efﬂux,
and crystalline particles such as silica and uric acid crystals [28].
Increasing data have demonstrated a signiﬁcant role for the NLRP3
inﬂammasome in AD (reviewed in [30]. Double transgenic mice that
overexpress human APP with familial AD mutations and have a
deﬁciency in the NLRP3 inﬂammasome showed a reduction in AD pa-
thology and were protected from the ensuing cognitive defects [31].
Earlier in vitro studies demonstrated that ﬁbrillar Aβ stimulated
NLRP3 inﬂammasome activation and IL-1β production in microglia
and this processwas shown to involve phagocytosis, lysosomal damage,
and release of cathepsin B [32]. Another report conﬁrmed ﬁbrillar Aβ-
stimulated inﬂammasome activation but demonstrated that pre-
priming of the inﬂammasome was required [33]. However, it was re-
cently shown that Aβmay provide both priming and activation signals
[34].
We have recently demonstrated that Aβ(1-42) protoﬁbrils, but not
Aβ(1-42) ﬁbrils, are robust activators of microglia [35] and that these
soluble ﬁbrillar precursors can trigger proinﬂammatory events viaToll-like receptors (TLRs) [20]. In the current study we investigated
the role of MyD88 in both Aβ(1-42) protoﬁbril-induced cytokine pro-
duction and NLRP3 inﬂammasome activation. During this investigation,
we identiﬁed multiple points of regulation by Aβ protoﬁbrils in both
pathways including new insights into the IL-1β secretion process.
2. Experimental procedures
2.1. Preparation of Aβ peptides
Aβ(1-42) was obtained from W. M. Keck Biotechnology Resource
Laboratory (Yale School of Medicine, New Haven, CT) in lyophilized
form and stored at−20 °C. Aβ(1-42) peptides were dissolved in 100%
hexaﬂuoroisopropanol (HFIP) (Sigma-Aldrich, St. Louis) at 1 mM, sepa-
rated into aliquots in sterile microcentrifuge tubes, and evaporated un-
covered at room temperature overnight in a fume hood. The following
day the aliquots were vacuum-centrifuged to remove any residual
HFIP and stored in dessicant at−20 °C.
2.2. Size exclusion chromatography
Aβ protoﬁbrils were isolated as previously described [35]. Brieﬂy,
yophilized Aβwas dissolved in 50mMNaOH to yield a 2.5mMAβ solu-
tion followed by dilution to 250 μM Aβ in preﬁltered artiﬁcial cerebro-
spinal ﬂuid (aCSF, 15 mM NaHCO3, 1 mM Na2HPO4, 130 mM NaCl,
3 mM KCl, pH 7.8). The solution was then centrifuged at 18,000 ×g for
10 min and the supernatant was fractionated on a Tricorn Superdex
75 10/300 GL column (GE Healthcare) using an AKTA FPLC system (GE
Healthcare). Prior to injection of Aβ, the Superdex 75 columnwas coat-
ed with sterile bovine serum albumin (Sigma) to prevent any non-
speciﬁc binding of Aβ to the column matrix. Following a 1 mL loading
of the sample, Aβ was eluted at 0.5 mL min−1 in aCSF and 0.5 mL frac-
tions were collected and immediately placed on ice. Aβ concentrations
were determined in line by UV absorbance using an extinction coefﬁ-
cient of 1450 cm−1 M−1 at 280 nm.
2.3. Primary microglia isolation
Primarymurinemicrogliawere obtained fromwild-type (WT) C57BL/
6 (Harlan Laboratories) orMyD88−/−mice (gift from Dr. Tammy Kielian,
University of Nebraska Medical Center). Microglia were isolated as previ-
ously described [35,36] from3–4day oldmouse pups. Brieﬂy, brainswere
isolatedunder sterile conditions,minced, and trypsinized. Thebrain tissue
was then resuspended in complete DMEM containing 10% fetal bovine
serum (FBS), 4 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin and 0.25 μg/mL amphotericin-B, OPI medium supplement
(oxalocetate, pyruvate, insulin), and 0.5 ng/ml recombinant mouse
granulocyte-macrophage colony-stimulating factor (GM-CSF). The cell
suspension was ﬁltered, centrifuged, resuspended in complete medium
and seeded into 150 cm2 ﬂasks. Cells were cultured at 37 °C in 5% CO2
until conﬂuent (1–2 weeks) and microglia were selectively harvested
from the adherent astrocyte layer by overnight shaking of the ﬂask at
37 °C in5%CO2 and collection of themedium. Theﬂaskswere replenished
with fresh medium, and incubated further to obtain additional microglia.
Typically, this procedurewas repeated 3–4 times for oneﬂaskwithout re-
moval of the astrocyte layer.
2.4. Cell stimulation assay
For cellular studies, WT and MyD88−/− primary murine microglia
were collected as described above by overnight shaking, collection of
the cells, and seeding in a sterile 96-well cell culture plate for 24 h at a
density of 5 × 105 cells/ml in growth medium with serum and GM-CSF
(0.1 mL per well). Prior to cell treatment, medium was replaced with
0.1 mL medium lacking FBS and GM-CSF. Cells were then treated with
Aβ (15 μM) or TLR stimuli ultra-pure lipopolysaccharide (LPS, 10 ng/ml
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(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-
[S]-lysine (Pam3CSK4, 100 ng/ml, InvivoGen), or (S,R)-(2,3-
bispalmitoyloxypropyl)-Cys-Gly-Asp-Pro-Lys-His-Pro-Lys-Ser-Phe
(FSL-1, 100 ng/ml, InvivoGen). The cells were incubated at 37 °C for
the indicated times in 5% CO2, the medium was collected and stored
at −20 °C for subsequent analysis by enzyme-linked immunosor-
bent assay (ELISA) and the cells were lysed for either intracellular
ELISA analysis or mRNA analysis. The background cellular response
was assessed using the particular buffer vehicle for the Aβ. Inhibition
of secreted IL-1β by the caspase-1 inhibitor z-YVAD-fmk (EMD
Millipore) was carried out by dissolution of the inhibitor in 100%
DMSO. Microglia were pretreated for 30 min with ﬁnal concentra-
tions of 0, 5, 10, and 20 μM z-YVAD-fmk containing 0.05% DMSO
followed by treatment with 15 μM Aβ(1-42) protoﬁbrils for 6 h at
37 °C and 5% CO2. The conditioned medium was then collected and
analyzed by ELISA for secreted IL-1β.
2.5. ELISA
Levels of murine TNFα and IL-1β were determined by ELISA as
previously detailed [20]. Brieﬂy, 96-well plates were coated overnight
withmonoclonal anti-mouse TNFα or IL-1β capture antibody (R&DSys-
tems), washed with phosphate-buffered saline (PBS) containing 0.05%
Tween-20 and blocked with PBS containing 1% bovine serum albumin
(BSA), 5% sucrose and 0.05% NaN3 following by a wash step. Successive
treatments with washing in between were done with samples or stan-
dards, biotinylated polyclonal anti-mouse TNFα or IL-1β detection anti-
body (R&D Systems) in 20 mM Tris with 150 mM NaCl and 0.1% BSA,
streptavidin–horseradish peroxidase (HRP) conjugate, and equal vol-
umes of HRP substrates 3,3',5,5'-tetramethylbenzidine and hydrogen
peroxide. The reaction was stopped by the addition of 1% H2SO4 solu-
tion. The optical density of each sample was analyzed at 450 nm with
a reference reading at 630 nm using a SpectraMax 340 absorbance
plate reader (Molecular Devices, Union City, CA). The concentration of
TNFα and IL-1β in the experimental samples was calculated from a
mouse TNFα or IL-1β standard curve of 15–16,000 pg/ml. When neces-
sary, samples were diluted to fall within the standard curve. TNFα and
IL-1β concentrations for absorbance values below the lowest 15 pg/ml
standard were determined by extrapolation of the standard curve re-
gression line. Intracellular pro-IL-1β was determined using a mouse
IL-1β pro-form ELISA set (eBioscience 88-8014). The procedure was
done according the manufacturer guidelines and is similar to the
TNFα and IL-1β described above. The concentration of pro-IL-1β in
the experimental samples was calculated from a mouse pro-IL-1β stan-
dard curve of 15–2000 pg/ml. All cytokine levels are reported as pg/mL
and are based on the output from 104 cells in eachwell. For intracellular
measurements with combined wells used for extract preparation, the
cytokine concentrations have been normalized to reﬂect 104 cells per
well.
2.6. Determination of mRNA levels
Following treatment of microglia and removal of the medium,
total RNA was obtained using a GeneJET RNA puriﬁcation kit
(Fermentas). The procedure was done according to manufacturer
guidelines. RNA was collected from ﬁve replicate samples for each
condition to increase the amount of mRNA in each condition. Total
RNA concentration was determined using 260/280 nm absorbance
ratio and the highest amount of total RNA available up to 1 μg was
concentrated. Genomic DNA was removed in the presence of an
RNase inhibitor and each sample was stored on ice. Synthesis of
cDNA was done according to manufacturer guidelines (RevertAid
Kit, Fermentas) and cDNA samples were stored at −20 °C. Selected
sequences were ampliﬁed using real-time quantitative (RT-q) PCR
(C1000 Thermocycler, BioRad, Hercules, CA) and the SYBR Greenmode of detection. Primers (Invitrogen) (TNFα, TTCCCAAATGGCCT
CCCTCTCATC, forward, TCCTCCACTTGGTGGTTTGCTAC, reverse; IL-
1β, CCTGTGTAATGAAAGACGGCACAC, forward, ATTGATTGGGATCC
ACACTCTCC, reverse) and cDNA samples were subjected to a three-
step cycling protocol using Bio-Rad CFX Manager software. mRNA
levels were calculated and reported in terms of relative quantity
(RQ). RQ was determined from the equation RQ = E^(Cq, control −
Cq, stimulated), where Cq is the quantiﬁcation cycle value obtained
from the ﬂuorescence ampliﬁcation plot and E is efﬁciency with a
value of 2. In numerous experiments β-actin was used as an internal
control and did not vary signiﬁcantly between samples regardless of
microglia stimulation state.
2.7. Western blot
Extracts of treated primary microglia were prepared by removal of
the conditioned medium and lysis with RIPA buffer (20 mM Tris
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% deoxycholic
acid, and 0.1% SDS) supplemented with protease inhibitor cocktail
(Sigma). Five replicatewells were combined for each condition. Collect-
ed lysateswere centrifuged at 9000 ×g to remove cell debris and the su-
pernatants were mixed 1:1 with Laemmli SDS sample buffer (Bio-Rad)
containing 5% β-mercaptoethanol. Samples were denatured (95 °C,
5 min) and separated on 15% Tris-HCl gels (Ready Gel, Bio-Rad) under
denaturing conditions (25 mM Tris, 192 mM glycine, 0.1% SDS at
pH 7.8) using a Mini Protean 3 Cell (Bio-Rad).
Gels were transferred to PVDF membrane (Milipore) in transfer
buffer containing 25 mM Tris base, 192 mM glycine, and 10% methanol
at pH 8.3 using a Tank VEP-2 electroblotting system (Owl Separation
Systems). Following protein transfer, the membrane was blocked for 1
h at 25 °C with PBS containing 5% nonfat dry milk and 0.1% Tween 20)
and probed with a 1:500 dilution of 3ZD anti-IL-1β monoclonal anti-
body (National Cancer Institute) in PBS with 1% milk and 0.1% Tween
20 overnight at 4 °C and a 1:1000 dilution of goat anti-mouse IgG-
HRP secondary antibody (R & D systems) in the same buffer for 1 h at
25 °C. Protein detection was accomplished using ECL Western Blotting
Substrate Detection reagents (Pierce) and exposure to ﬁlm (Kodak).
Themembranewas strippedwith RestoreWestern Blot Stripping Buffer
(Thermo Scientiﬁc) and re-probed with α-tubulin (TU-02) (Santa Cruz
Biotechnology) as a loading control.
2.8. Statistical analysis
Statistical analysis was performed to determine the conﬁdence limit
at which two measurements were statistically different. In most cases
one-way analysis of variance (ANOVA) was used although some data
were treated with univariate ANOVA. Statistical differences with a p-
value greater than 0.05 were considered insigniﬁcant.
3. Results
3.1. MyD88-dependent microglia stimulation and priming of the NLRP3
inﬂammasome by Aβ(1-42) protoﬁbrils
Aβ(1-42) protoﬁbrils were prepared as previously described in a
modiﬁed artiﬁcial cerebrospinal ﬂuid (aCSF) buffering system and iso-
lated by SEC [37]. This preparation produced a Superdex 75 void-
volume fraction enriched in curvilinear Aβ protoﬁbrillar structures
less than 100 nm in length with a range of hydrodynamic radii from
10 to 40 nm(mean21 nm) [37].Wehave previously shown that soluble
protoﬁbrils prepared in either F-12 cell culture medium or aCSF bound
and signiﬁcantly enhanced thioﬂavin T (ThT) ﬂuorescence emission at
480 nm whereas isolated Aβ(1-42) monomers eluted in the included
volume did not display any ThT ﬂuorescence [35,37]. In the current
study, primary murine microglia were treated with SEC-isolated Aβ(1-
42) protoﬁbrils for different incubation times and mRNA levels for
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Fig. 2. TNFα and IL-1β mRNA production is reduced in the MyD88−/− microglia in
response to protoﬁbrils. SEC-isolated Aβ(1-42) protoﬁbrils were incubated with WT pri-
mary microglia and MyD88−/− (KO) microglia at a ﬁnal concentration of 15 μM for 2 h
in serum-free medium. After 2 h the total RNA was collected and TNFα (Panel A) and IL-
1β (Panel B) mRNA levels were quantiﬁed by qPCR as described in Fig. 1 legend. Data
bars represent themean± std error of n=8 qPCR replicates. Protoﬁbril-treatedmicroglia
were compared to aCSF-treated microglia to determine relative quantity. When compar-
ing WT and MyD88−/− microglia, experiments were always done on the same day.
Statistical analysis conﬁrmed a signiﬁcant difference (*p b 0.001) between the WT and
MyD88−/−microglial TNFα and IL-1βmRNA response.
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described in the Methods. Protoﬁbrils signiﬁcantly elevated TNFα
mRNA by 2 h followed by a rapid drop of the transcript at the 4 and 6 h
time points (Fig. 1A). Aβ(1-42) protoﬁbrils also induced signiﬁcant
levels of IL-1β mRNA in primary murine microglia. The time course
was similar to TNFα in that the majority of stimulated IL-1β mRNA
occurred at 2 h (Fig. 1B).
A role for several TLRs has been demonstrated in the recognition of
extracellular Aβ and initiation of proinﬂammatory events in mono-
cyte/macrophages andmicroglia [19–24]. One of the cytoplasmic medi-
ators of signal transduction linking TLR stimulation and NFκB activation
is the adaptor protein MyD88 [18]. In order to determine the contribu-
tion of TLR-MyD88 signaling in Aβ protoﬁbril-induced cytokine mRNA
upregulation, microglia isolated from either WT or MyD88−/− mice
were compared for their responsiveness to Aβ(1-42) protoﬁbrils. Wild
type microglia again showed marked increases in both TNFα and IL-
1βmRNA in response to treatment with Aβ(1-42) protoﬁbrils (Fig. 2).
However, this response was dramatically reduced in MyD88−/− mi-
croglia compared to WT microglia. Both TNFα and IL-1β mRNA levels
were close to that of buffer control in the MyD88−/−microglia (Fig. 2).
The mRNA ﬁndings revealed a TLR/MyD88-dependent transcrip-
tional activation process triggered by Aβ(1-42) protoﬁbrils. This
pathwaywas explored in further detail bymeasuring intracellular levels
of pro-IL-1β using a pro-form speciﬁc ELISA. The speciﬁcity was con-
ﬁrmed by the observation that serial dilutions of mature IL-1β protein
standard were not detected by the pro-IL-1β-speciﬁc antibodies. Only
pro-IL-1β and not mature IL-1β standard curves were able to be con-
structed (Supplementary Fig. 1). Analysis of microglial extracts
following removal of the conditioned medium and washing of the
cells yielded several observations. First, the presence of existing stores
of pro-IL-1β in unstimulated WT and MyD88−/− microglia was con-
ﬁrmed at 6 h (Fig. 3) which indicated some level of underlying basal
NLRP3 inﬂammasome priming in the isolated primary microglia. This
may be inadvertently caused by the isolation and culturing process or
purposefully established as an intracellular reservoir enabling a rapid
microglial response to stimuli. Secondly, a signiﬁcant increase in pro-
IL-1β levels compared to control treatment occurred after treatment
of the WT microglia with Aβ(1-42) protoﬁbrils for 6 h (p b 0.005)
(Fig. 3) when a one-way ANOVAwas used to compare control and stim-
ulated in WT microglia. This same analysis did not show a signiﬁcant
difference in MyD88−/−microglia (p N 0.05) (Fig. 3). Further analysis
of the time points by univariate ANOVA considering both treatment
and the presence of MyD88 showed a lesser, but still signiﬁcant, differ-
ence (p b 0.05) between the WT and MyD88−/− microglial response.
Pro-IL-1β production was somewhat variable and the difﬁculty inTNF
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Fig. 1. Aβ(1-42) protoﬁbrils formed and isolated in aCSF are signiﬁcant stimulators of
TNFα and IL-1β transcription. SEC-isolated Aβ(1-42) protoﬁbrils in aCSF were incubated
with WT primary microglia at a ﬁnal concentration of 15 μM for 1, 2, 4, and 6 h in
serum-free medium. At each time point the cells were lysed for total RNA extraction.
TNFα (Panel A) and IL-1β (Panel A) mRNA levels were measured by qPCR as described
in the Methods. The term relative quantity is described in the Methods and represents
the mRNA comparison between microglia treated with Aβ(1-42) protoﬁbrils and those
treated with buffer control. β-Actin was used as an internal control in separate experi-
ments and did not vary signiﬁcantly between samples. Data bars represent the mean ±
std error of n = 8 qPCR replicates. TNFα and IL-1βmRNA levels at 2 h were signiﬁcantly
different than any other time point (*p b 0.001).quantitatively measuring pro-IL-1β stimulated by Aβ(1-42) protoﬁbrils
may be partially explained by the subsequent observation that
protoﬁbrils also activate the NLRP3 inﬂammasome, thus creating a dy-
namic pool of pro-IL-1βwith a balance between production and conver-
sion to mature IL-1β.3.2. Intracellularmature IL-1β production induced by Aβ(1-42) protoﬁbrils
in primary microglia
Recent evidence has demonstrated a role for Aβ in the activation of
the NLRP3 inﬂammasome [31–34]. The result of NLRP3 complex assem-
bly and activation is caspase-1 mediated proteolytic cleavage of pro-IL-
1β (31 kD) to the mature form of the protein (17 kD). In order to study
intracellular inﬂammasome processing of pro-IL-1β to mature IL-1β by
Aβ(1-42) protoﬁbrils in microglia, immunoblots were combined with
ELISA measurements for evaluation of both IL-1β species. Primary mu-
rine microglia were treated with isolated Aβ(1-42) protoﬁbrils and at
increasing incubation times, the cells were lysed to probe intracellular
IL-1β levels. Immunoblot analysis using 3ZD antibody,which recognizes
both pro andmature forms of IL-1β, showed a consistent pool of pro-IL-
1β throughout the time course for both unstimulated and Aβ-
stimulated microglia (Fig. 4A). Signiﬁcant levels of intracellular mature
IL-1βwere not observed until the 4 and 6 h Aβ-stimulated time points.
ELISA-based IL-1β measurements, using a different set of antibodiespr
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Fig. 3.Aβ(1-42) protoﬁbrils stimulate intracellular pro-IL-1β production inmicroglia. SEC-
isolated Aβ(1-42) protoﬁbrils in aCSF (gray bars) or aCSF buffer alone (black bars) were
incubated with WT and MyD88−/− (KO) primary microglia at a ﬁnal concentration of
15 μM for 6 h in serum-free medium. After incubation the conditioned medium was re-
moved, each cell well was treatedwith 100 μL of lysis buffer and the extract was collected
tomeasure intracellular pro-IL-1β protein by ELISA. Data bars represent the average± std
error of n = 5 replicates. One-way ANOVA looking at WT and KO microglia individually
showed a signiﬁcant difference between control and protoﬁbril-stimulated WT microglia
(p b 0.005) with no statistical difference in the KOmicroglia. Univariate ANOVA consider-
ing both treatment and the presence ofMyD88 showed a lesser, but still signiﬁcant, differ-
ence (*p b 0.05) between the WT and KO microglial response.
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Fig. 5. Aβ(1-42) protoﬁbrils stimulate rapid IL-1β secretion but a slower time-dependent
TNFα secretion. SEC-isolated Aβ(1-42) protoﬁbrils in aCSF were incubated with WT
primary microglia at a ﬁnal concentration of 15 μM for 1, 2, 4, and 6 h in serum-free me-
dium. At each time point the conditioned microglial medium was collected for TNFα
and IL-1β protein determination by ELISA. Panel A. TNFα protein levels were determined
from the supernatant of individually treated wells. Data bars represent the mean ± std
error of n = 5 replicates at each time point. Control treatments with an equal volume of
aCSF produced very low TNFα levels compared to protoﬁbrils ranging from 36 to
290 pg/ml (b4% of the Aβ-stimulated response) at the different time points and were
subtracted fromAβ-stimulated samples. TNFα levels at each successive time point are sta-
tistically different than the preceding time point (p b 0.001). Panel B. IL-1β protein levels
weremeasured in the samemanner as for TNFα. Control treatmentswith an equal volume
of aCSF produced IL-1β levels of 1 pg/ml and were subtracted from Aβ-stimulated sam-
ples. The length of incubation time had no statistical difference on the amount of secreted
IL-1β (p N 0.05).
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same time-dependent production of intracellular mature IL-1β ob-
served by immunoblot was also detected by IL-1β ELISA with the
most substantial increases at 4 and 6 h (Fig. 4C). The IL-1β ELISA anti-
bodies likely detect both pro and mature IL-1β forms. However, the
large change in IL-1β levels as measured by ELISA (Fig. 4C)
corresponded with the clearly observable increase in mature IL-1β in
the immunoblot (Fig. 4A) suggesting that marked increase was thema-
ture protein. Intracellular cell extracts were prepared from multiple
wells (n=5)using a smaller volume of lysis buffer to increase detection
by immunoblot. This method resulted in relatively high intracellular
mature IL-1β concentrations when measured by ELISA. Therefore,
these levels were normalized to reﬂect the number of wells (104 cells
per well) and the volume of the extract. A longer time course was
conducted that extended the incubation time of the Aβ(1-42)
protoﬁbrils with primary microglia to 24 h (Fig. 4B, D). Immunoblot
analysis again showed the pro and mature form of IL-1β (Fig. 4B) and
both immunoblot and ELISA measurements (Fig. 4D) further demon-
strated that intracellular IL-1β continued to increase after stimulation
of the microglia with Aβ(1-42) protoﬁbrils.
The time course for the marked build-up of intracellular mature IL-
1β ﬁts a model whereby Aβ triggers the TLR/MyD88 pathway leading
to transcription of IL-1βmRNA, synthesis of pro-IL-1β, and conversion
of pro to mature IL-1β. These data show that the last step is also
triggered by Aβ(1-42) protoﬁbrils. Subsequent experiments testing
this model compared intracellular mature IL-1β levels between WT
and MyD88−/− microglia after treatment with Aβ(1-42) protoﬁbrils.
While WT microglia produced signiﬁcant levels of intracellular IL-1β,
MyD88−/− microglia were severely diminished in their ability to
produce intracellular mature IL-1β (Fig. 4E). At 6 h, MyD88−/−
microglia IL-1β levels were only 8% of WT microglia (Fig. 4E) and no
IL-1β above control was observed at 24 or 48 h after treatment of
MyD88−/−microglia with Aβ(1-42) protoﬁbrils (data not shown).3.3. Time course of Aβ(1-42) protoﬁbril-inducedmicroglial TNFα and IL-1β
protein secretion
Primary murine microglia were treated with SEC-isolated Aβ(1-42)
protoﬁbrils for different incubation times and secreted protein levels for
proinﬂammatory cytokines TNFα and IL-1βwere quantiﬁed in the con-
ditioned medium as described in the Methods. Protoﬁbrils induced a
steady increase in secreted TNFα protein during the 6 h incubation
(Fig. 5A). Much of the TNFα protein secretion occurred after the
2281S.E. Terrill-Usery et al. / Biochimica et Biophysica Acta 1842 (2014) 2276–2285majority of the TNFα mRNA had been transcribed (Fig. 1A). Control
treatments with aCSF buffer alone were just under 3% of the
protoﬁbril-stimulated levels. The time course for Aβ(1-42) protoﬁbril-
induced IL-1β secretionwasmuch different than for TNFα. Unexpected-
ly,maximal levels of secretedmature IL-1β proteinwere observed at 1 h
and this levelwasmaintained through the 6 h collection time point. This
observation was surprising since maximal IL-1β protein secretion by
Aβ(1-42) protoﬁbrils occurred prior to induction of maximum IL-1β
mRNA transcription (Fig. 1B). The ﬁndings revealed several things,
(1) the apparent presence of a small pre-existing level of pro-IL-1β in
the isolated primary microglia, (2) that Aβ-activation of the NLRP3
inﬂammasome occurs much more rapidly than Aβ stimulation of the
TLR/MyD88 pathway and cytokine transcription/translation, and
(3) the build-up of intracellularmature IL-1βdoes not necessarily trans-
late into increased IL-1β secretion. Importantly, the data again demon-
strated that Aβ(1-42) protoﬁbrils did not need a secondary molecule,
or an additional stimulus, to produce mature IL-1β protein as is the
case with LPS (Signal 1) and ATP (Signal 2) [18]. Additional time-
dependent experiments found that maximal levels of secreted IL-1β
protein could be observed by 15 min (the earliest time point tested)
and there was no residual secreted IL-1β remaining from the overnight
plating of the microglia (data not shown). From these experiments, it
was apparent that the microglia rapidly secreted a quantum of mature
IL-1β after Aβ(1-42) protoﬁbril stimulus and the time point at which
the conditioned medium was collected was immaterial. This same pat-
tern of rapid IL-1β secretion was observed repeatedly. In fact, during
the experiments presented in Fig. 4A–D, secreted IL-1β was also mea-
sured in the conditioned medium collected prior to cell lysate prepara-
tion. It did not matter whether the samples were collected at 0.25, 1, 2,
4, 6 or 24 h, a similar quantum of secreted mature IL-1β was found in
the medium (Supplementary Fig. 2) despite the signiﬁcant increase inKO
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Fig. 6. Aβ(1-42) protoﬁbril-induced TNFα secretion, but not rapid IL-1β secretion, is dependen
SEC-isolated Aβ(1-42) protoﬁbrils were incubated with WT and MyD88−/− (KO) primary mic
serum-free medium. Secreted TNFαwas measured by ELISA in the conditioned medium. Data
periments) for LPS, Pam3CSK4, and FSL-1, and n=6 replicates (triplicates from2 separate exper
were 21667, 4584, 2888, and 12652 pg/ml for LPS, Pam3CSK4, FSL-1, and Aβ(1-42) protoﬁbrils
the TNFα response andwere subtracted fromTLR ligand- or Aβ-stimulated samples. Statistical a
for all four treatments. Panel B. SEC-isolated Aβ(1-42) protoﬁbrils were incubated withWT pri
and 6 h in serum-freemedium. Secreted IL-1βwasmeasured by ELISA in the conditionedmediu
an equal volume of aCSF produced 1 pg/ml IL-1β at all time points for both theWT microglia a
analysis showed no signiﬁcant difference between theWT andMyD88−/− results at any time p
MyD88−/− primarymicroglia (KO)with Aβ(1-42) protoﬁbrils (15 μM) for 6 h in serum-freeme
secreted data bars are the average ± std error for n = 5 replicates. Control treatments with an
statistical difference was observed between the WT and MyD88−/− response (p N 0.05).intracellular mature IL-1β shown in Fig. 4C and D. The measurement
of both secreted and intracellular mature IL-1β from the same cells pro-
vided even stronger evidence that the rapid IL-1β secretion stimulated
by Aβ(1-42) protoﬁbrils was temporally distinct from, and not fully de-
pendent on, Aβ-triggered intracellular mature IL-1β accumulation.
3.4. MyD88 impacts Aβ(1-42) protoﬁbril-induced microglial TNFα and IL-
1β protein secretion differently
TNFα protein secretion was compared betweenWT and MyD88−/−
microglia after stimulation with three known TLR ligands, LPS (TLR4),
PAM3CSK4 (TLR2/1) and FSL-1 (TLR2/6). TNFα levels weremarkedly re-
duced in MyD88−/− microglia in response to LPS (92% reduction) but
not completely abolished conﬁrming bothMyD88-dependent and inde-
pendent pathways (Fig. 6A). However, the absence ofMyD88 complete-
ly eliminated TNFα production in response to PAM3CSK4 or FSL-1
(Fig. 6A). The results for the TLR ligands presented in Fig. 6were obtain-
ed using 100 ng/ml of each ligand although additional experiments at
10 ng/ml ligand concentration gave similar results (data not shown).
Themicroglial TNFα response to Aβ(1-42) protoﬁbrils was signiﬁcantly
lowered in the absence of MyD88 (88% reduction) indicating that the
adaptor protein was a major mediator of Aβ(1-42) protoﬁbril-induced
TNFα production. The remaining response suggested additional path-
ways for mediating TNFα secretion that were independent of MyD88.
The levels of secreted mature IL-1β protein were evaluated in WT
microglia medium after treatment with stimuli. Neither LPS, PAM3CSK4,
nor FSL-1 alone inducedmature IL-1β protein secretion inWTmicroglia
(data not shown) conﬁrming that these TLR ligands do not activate the
NLRP3 inﬂammasome without an additional stimulus. Aβ(1-42)
protoﬁbrils, however, induced similar levels of secreted IL-1β protein
in both WT and MyD88−/− microglia conditioned medium collectedIL
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Fig. 8.Aβ protoﬁbril-induced rapid IL-1β secretion is not sustained but is repeatable. Panel
A. Primary microglia were exposed to SEC-isolated Aβ(1-42) protoﬁbrils (15 μM) and
allowed to incubate at 37 °C for 1 h. The conditioned medium was then removed, fresh
medium applied, and collected at 2 h. This process was repeated again for the 4 h analysis.
No further IL-1βwas secreted compared to the 1 h time point (p b 0.001). Panel B. Exper-
iments were conducted as described in Panel A, although Aβ(1-42) protoﬁbrils (15 μM)
were added with the fresh medium at 1 and 2 h. Data bars represent the average ± std
error of n=5 replicates. No statistical difference (NS)wasnoted in the amount of secreted
IL-1β elicited by each successive Aβ(1-42) proﬁbril treatment (p N 0.05).
2282 S.E. Terrill-Usery et al. / Biochimica et Biophysica Acta 1842 (2014) 2276–2285after 1, 2, 4, or 6 h of stimulation (Fig. 6B). The observation that the
absence of MyD88 did not decrease protoﬁbril-induced IL-1β protein
secretion yet dramatically reduced IL-1βmRNA (Fig. 2) was the second
line of evidence suggesting a potential intracellular reservoir of pro- or
mature IL-1β produced prior to stimulation of the microglia with
Aβ(1-42) protoﬁbrils.
3.5. Mechanisms of Aβ(1-42) protoﬁbril-induced IL-1β secretion
Two possible explanations for the disconnect between TLR/MyD88-
mediated IL-1βmRNA production and mature IL-1β protein secretion
were (1) rapid Aβ(1-42) protoﬁbril-triggered microglial secretion of
existing mature IL-1β reservoirs, or (2) rapid activation of the NLRP3
inﬂammasome by Aβ(1-42) protoﬁbrils followed by caspase-1-
mediated cleavage of existing pro-IL-1β reservoirs and secretion of ma-
ture IL-1β. Both of these scenarios would presumably occur prior to
TLR/MyD88-mediated IL-1β transcription and translation to pro-IL-1β
protein. In order to investigate these hypotheses, we examined the
rapid secretion process in more detail. First, stimulation of microglia
with a concentration range of Aβ(1-42) protoﬁbrils showed a dose-
dependent effect on secreted IL-1β (Fig. 7A) and indicated that the
level of secreted mature IL-1β initially triggered by Aβ(1-42)
protoﬁbrils correlated with the magnitude (concentration) of the stim-
ulus. Second, the amount of secreted IL-1β triggered by Aβ protoﬁbril
stimulation was lowered in a dose dependent manner by the caspase-
1 inhibitor z-YVAD-fmk (Fig. 7B). This ﬁnding supported the case that
the rapidly secreted IL-1β originated from existing reservoirs of pro-
IL-1β.
In all of the previous experiments in this report, and inmost cases in
the literature, the microglia were typically treated once with the Aβ(1-
42) protoﬁbril stimulus and then secreted IL-1β was analyzed at in-
creasing incubation times. In order to test whether microglia elicited a
sustained response to the initial Aβ stimulus, experiments were con-
ducted where the cell medium was collected, replaced, and collected
again at increasing times after microglial exposure to Aβ(1-42)
protoﬁbrils. Using this procedure, secreted IL-1β was only observed
after the ﬁrst collection of the conditioned medium (Fig. 8A) indicating
that the protoﬁbril-induced secretion occurred right after stimulation
and was not sustained. Repeated stimulation of the same microgliaA PF (μM)
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Fig. 7. Dose-dependent IL-1β secretion in primary microglia induced by Aβ(1-42)
protoﬁbrils. Panel A. Primary microglia were treated with SEC-isolated Aβ(1-42)
protoﬁbrils (1, 5, 10, and 15 μM) and incubated for 6 h. Secreted IL-1β levels were mea-
sured in the conditioned medium by ELISA. Data bars represent the average ± std error
of n = 3 replicates for each condition. Statistical differences (p b 0.05) in secreted IL-1β
elicited by eachAβ protoﬁbril concentration are denotedwith an asterisk. Panel B. Primary
microglia were pretreated as described in the Methods with increasing concentrations of
the caspase-1 inhibitor z-YVAD-fmk or 0.5% DMSO vehicle followed by 15 μM Aβ(1-42)
protoﬁbrils. A control treatment (C) that contained 0.5% DMSO but neither z-YVAD-fmk
or Aβwas also included. Secreted IL-1β levels were measured in the conditioned medium
by ELISA. Data bars represent the average ± std error of n = 3 replicates for each condi-
tion. Statistical differences (p b 0.05) in secreted IL-1β elicited by Aβ protoﬁbrils in the ab-
sence or presence of the inhibitor are denoted with an asterisk.with Aβ(1-42) protoﬁbrils produced similar quantum of secreted IL-
1β each time (Fig. 8B). This implied that the microglial IL-1β secretion
machinery was not desensitized, or depleted, by Aβ protoﬁbrils. These
same ﬁndings were obtained in MyD88−/−microglia (Supplementary
Fig. 3), again demonstrating MyD88-independent reservoirs of pro or
mature IL-1β.
It was noted in Fig. 4 and Supplementary Fig. 2 that the Aβ(1-42)
protoﬁbril-induced accumulation of intracellular IL-1β at longer time
points (6, 10, 24 h) did not result in a corresponding increase in secreted
mature IL-1β protein. These results suggested that an additional Aβ
stimulus may be needed to trigger release of the accumulated intracel-
lular mature IL-1β. In order to test this idea, primary microglia were
treated with Aβ(1-42) protoﬁbrils for 6 h to allow intracellular mature
IL-1β accumulation, and then treated a second time. However, a sub-
stantial increase in secreted mature IL-1β was not observed (Fig. 9A)
even though intracellular IL-1βmarkedly increased during the initial 6
h exposure of Aβ(1-42) protoﬁbrils to the microglia (Fig. 9B). As in
Fig. 8, the second Aβ(1-42) protoﬁbril stimulus provoked the same
quantum of secreted IL-1β as the initial stimulus despite the substantial
increase in intracellular IL-1β. It was evident from the cumulative data
that Aβ(1-42) protoﬁbrils stimulated both a time- and MyD88-
dependent accumulation of intracellular mature IL-1β and secreted
TNFα in microglia. However, the stimulation of pro-IL-1β and the
build-up of mature IL-1β inside the cell did not translate into greater
levels of secreted IL-1β. In fact, the Aβ(1-42) protoﬁbrils evoked a
rapid quantized secretion of IL-1β prior to upregulation of the intracel-
lular pathway and this secretion process was limited, or perhaps regu-
lated, in its response. These ﬁndings provide further detail into the
mechanisms by which Aβ(1-42) protoﬁbrils prime and activate the
NLRP3 inﬂammasome.
4. Discussion
Numerous studies have identiﬁed aggregated Aβ as a danger-
associated molecular pattern (DAMP). DAMPs have qualities similar to
PAMPsbut are endogenous, rather than external, pathogens. Theunique
structural characteristics acquired as Aβmonomers self-assemble into
oligomers and ultimately ﬁbrils give the protein proinﬂammatory prop-
erties. We have recently shown that Aβ(1-42) protoﬁbrils were far su-
perior to isolated Aβ(1-42) ﬁbrils in their ability to activate microglia
and they displayed no toxicity to the microglia as measured by XTT
cell viability assay [35].
TLRs, the primary recognition molecules of the innate immune sys-
tem, are major mediators of Aβ-triggered inﬂammation in monocyte/
macrophage and microglial cells. Previous studies have demonstrated
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Fig. 9. A second stimulus of microglia with Aβ protoﬁbrils secretion does not release accu-
mulated intracellular IL-1β. Primary microglia were exposed to SEC-isolated Aβ(1-42)
protoﬁbrils (15 μM) or aCSF buffer alone and allowed to incubate at 37 °C for 6 h. The con-
ditioned medium was then removed and one intracellular extract was prepared for each
condition (combination of ﬁve wells in 20 μL of lysis buffer). The measured intracellular
IL-1β response in pg/mL, which was much higher, was normalized based on the number
of wells and lysis buffer volume. For the remaining cells, fresh medium was applied
alongwith a second protoﬁbril (n= 5wells or replicates) or buffer treatment (n= 5 rep-
licates). After an additional 1 h incubation, the conditioned medium from each well was
removed separately and one cell extract was again prepared for each condition. Secreted
(Panel A) and intracellular (panel B) IL-1βwas determined by ELISA. IL-1β data bars rep-
resent the average± std error of n=5 replicates for secreted and one intracellular extract
for each condition. Statistically signiﬁcant differences between treatments are denoted
with an asterisk (p b 0.001). No statistical difference (NS) was found between the
microglial IL-1β response when treated with Aβ(1-42) protoﬁbrils for 6 h and again for
1 h (p N 0.05).
2283S.E. Terrill-Usery et al. / Biochimica et Biophysica Acta 1842 (2014) 2276–2285a role for TLR4 and TLR2 [19–23] and TLR4 and TLR6 [24] in cytokine
production triggered by aggregated Aβ. The intracellular TLR adaptor
protein,MyD88, has also been implicated inmicroglial inﬂammatory re-
sponses induced by Aβ [38].
The most widely-accepted 2-signal model [28] linking TLRs and the
NLRP3 inﬂammasome describes a “priming” of the immune cell where-
in TLR engagement, MyD88 signaling, and transcriptional activation
result in mRNA and protein production. For IL-1β, the pro-form of the
protein would be the priming product. The priming process is followed
by a second signal (e.g. ATP, K+ efﬂux) which triggers inﬂammasome
activation and cleavage of pro-IL-1β to IL-1β. The number of innate im-
mune pathways sensitive to Aβ stimulation has expanded over the last
ﬁve years and several reports have now characterized the interplay be-
tween Aβ and the NLRP3 inﬂammasome [31–34]. Some of these Aβ/
NLRP3 studies utilized LPS as a TLR/MyD88 priming agent to produce
pro-IL-1β and prime the inﬂammasome [32]. However, it has become
apparent that Aβ alone can stimulate both priming [24] and activation
of the inﬂammasome. Our current report clearly shows that this is the
case and that Aβ can provide both signals necessary to elicit mature
IL-1β production and secretion. There are likely other mechanistic
steps in microglia that link mature IL-1β formation and release from
the cell. A recent report delineated between intracellular and secretedmature IL-1β in microglia stimulated with LPS [39]. While this report
and others show that LPS alone does not induce IL-1β secretion, Savage
et al. found that LPS alone did trigger intracellular mature IL-1β
production. This suggests that there may be additional sites for
regulation for IL-1β metabolism or trafﬁcking including the secretory
process.
We have applied the current general model linking TLRs and the
NLRP3 inﬂammasome to the more speciﬁc situation of Aβ protoﬁbrils
and their effect on multiple innate immune pathways. The expanded,
but still partial, model brings together the observations presented
from the current study (Fig. 10). In this model, Aβ(1-42) protoﬁbrils
can trigger two signals with an additional potential effect on the
secretory process. Activation of the TLR/MyD88 pathway represents
Signal 1 and Aβ(1-42) protoﬁbrils stimulated a dramatic upregulation
of IL-1β and TNFαmRNA and an increase in pro-IL-1βwhichwas highly
dependent on the TLR/MyD88 pathway. Aβ(1-42) protoﬁbrils also
clearly provided Signal 2 which involves activation of the NLRP3
inﬂammasome and conversion of pro-IL-1β to mature IL-1β. Aβ(1-42)
protoﬁbrils stimulated time-dependent production of intracellular ma-
ture IL-1β that was notably reduced in MyD88−/−microglia likely due
to diminished priming of the inﬂammasome. Activation of the
inﬂammasome by ﬁbrillar Aβ has been demonstrated previously and
several reports have implicated a phagocytosis/lysosomal-leakage
mechanism by which the activation occurs [32–34]. This mechanism
has been incorporated into the Fig. 10 model.
Although TLR/MyD88 engagement is generally accepted as Signal 1,
theﬁrst responsewe observed to Aβ protoﬁbrilswas a rapid secretion of
mature IL-1β (b15 min). This novel rapid secretion process was not de-
pendent on Aβ protoﬁbril-induced, MyD88-mediated, priming of the
cells which occurred over a longer time period. Through the course of
our investigation we observed that the isolated primary microglia in
culture exhibited markers of low-level activation with measurable
levels of pro-IL-1β by Western blot and ELISA. The presence of existing
pro-IL-1β reservoirs is not uncommon in primary microglial cultures
and has been observed in several studies by Western blot [33,40,41].
This basal level of inﬂammasome priming in unstimulated microglia
may provide reservoirs of pro-IL-1β poised for rapid caspase-1 cleavage
and secretion. These pools of pro-IL-1βmay not exist in vivo unless trig-
gered by a separate event thatmay prime themicroglia for a rapid IL-1β
secretory response to Aβ.
The Aβ(1-42) protoﬁbril-triggered rapid IL-1β secretion, which
has not been demonstrated previously, was very reproducible and
occurred as a quantum of IL-1β. The secretion burst could be
repeatedly triggered by additional protoﬁbril stimulation and the
magnitude of IL-1β secretion was dependent on Aβ protoﬁbril con-
centration. The Aβ concentrations required to induce IL-1β secretion
were in the low micromolar range (5–15 μM). This Aβ concentration
range is similar to what we have previously observed for TNFα secre-
tion [35] and to other reports describing microglial activation by Aβ
[24,32–34]. While these concentrations are higher than the low
nanomolar range for normal circulating Aβ [42,43], it has been
shown that total Aβ is ~100–200-fold higher in AD brain homoge-
nates compared to controls [44]. Furthermore, it is possible that
local Aβ concentrations in areas of accumulation may be much
higher. A recent review by Lopez-Castejon and Brough discussed
ﬁve major mechanisms for IL-1β secretion [45]. These include
(1) exocytosis of IL-1β-containing secretory lysosomes, (2) release
of IL-1β from shed plasma membrane microvesicles, (3) fusion of
multivesicular bodies with the plasma membrane and subsequent
release of IL-1β-containing exosomes, (4) export of IL-1β through
the plasma membrane using speciﬁc membrane transporters, and
(5) release of IL-1β upon cell lysis. The last mechanism is not likely
since Aβ(1-42) protoﬁbrils are not toxic to microglia, IL-1β secretion
was not sustained, and IL-1β secretion could be re-evoked by Aβ
from the same cells (Figs. 8 & 9). A possible scenario is that Aβ(1-
42) protoﬁbrils can trigger rapid IL-1β secretion from microglia
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Fig. 10. Proposed model of Aβ(1-42) protoﬁbril stimulation of the TLR/MyD88 and NLRP3 inﬂammasome pathways.
2284 S.E. Terrill-Usery et al. / Biochimica et Biophysica Acta 1842 (2014) 2276–2285that have already attained some level of activation and either direct-
ly modulate the mature IL-1β secretory process or stimulate
inﬂammasome-mediated pro-IL-1β cleavage and mature IL-1β
secretion.
There are still remaining questions from this investigation. First, the
signiﬁcant time-dependent accumulation of intracellular IL-1β trig-
gered by Aβ protoﬁbrils without a corresponding increase in secreted
IL-1β was puzzling. It is possible that the secretion process may be
under further regulation or controlled in some manner to limit over-
secretion. Alternatively, the protoﬁbrils may have additional unknown
effects on the NLRP3 inﬂammasome or secretory machinery. Second,
what is the signiﬁcance or consequence of Aβ protoﬁbril-triggered
TLR/MyD88-dependent intracellular IL-1β production since it does not
immediately lead to secretion? Third, what is the role of other Aβ
forms in stimulating the TLR/MyD88 and NLRP3 inﬂammasome path-
ways and how does the response differ from protoﬁbrils?4.1. Conclusion
The ﬁndings presented in this report highlight differences between
Aβ(1-42) protoﬁbrils and other TLR ligands and NLRP3 inﬂammasome
activators. Furthermore, these ﬁndings demonstratemultiple sites of in-
nate immune regulation by Aβ protoﬁbrils. These sites include the IL-1β
secretory process, TLR priming, and NLRP3 inﬂammasome activation.
The multi-pronged interactions of Aβ with the innate immune system
and the complexities of the ensuing response are daunting but provide
a number of avenues for therapeutic intervention.Acknowledgements
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